title: Intracervical prostaglandin E2 gel. Safety for outpatient cervical ripening before induction of labor.
abstract: Cervical ripening prior to induction of labor is often necessary for medical complications of pregnancy. We proposed to prospectively determine the safety of administering prostaglandin E2 (PGE2) gel intracervically in an outpatient setting. Four hundred forty-six patients underwent 515 gel procedures as outpatients. Trained perinatal nurses placed 0.5 mg of PGE2, prepared in a standard methylcellulose base, in the intracervical canal. The PGE2 dose was administered every two hours for a total of three doses if labor did not start. The patient was sent home two hours after the last dose if she was not in active labor. Labor started in 90 patients (20%) during the gel procedure; they were admitted to the labor-and-delivery unit. The remaining patients were discharged. Eighty-eight patients (20%) were later admitted in active labor prior to scheduled induction. One patient (0.02%) was found to have occasional prolonged decelerations on admission and underwent a cesarean section two hours after admission; the Apgar scores were 8 and 9 and the arterial pH, 7.21. Hyperstimulation with excessive intrauterine activity caused significant deceleration of the fetal heart rate in four patients (0.8%), two of whom required transfer to the labor-and-delivery unit but none of whom needed a cesarean section for fetal distress. PGE2 gel can be administered safely intracervically as an outpatient procedure by trained perinatal nurses.
authors.affiliation: Division of Maternal-Fetal Medicine, Good Samaritan Regional Medical Center, Phoenix, Arizona 85006.
authors.forename: J P
authors.initials: JP
authors.lastname: Elliott
authors.forename: W H
authors.initials: WH
authors.lastname: Clewell
authors.forename: T G
authors.initials: TG
authors.lastname: Radin
mesh_terms: D000553:Ambulatory Care / Q000191:economics; D002584:Cervix Uteri / Q000187:drug effects; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005782:Gels; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D011247:Pregnancy; D011446:Prospective Studies
chemical_list: D005782:Gels; D015232:Dinoprostone